3.8 Editorial Material

Aducanumab: The first targeted Alzheimer's therapy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Medicine, General & Internal

Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

G. Caleb Alexander et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2021

Jeffrey Cummings et al.

Summary: Overall, the study highlights the urgent need for new treatments for Alzheimer's disease, and shows that a diverse range of drugs targeting the biology of AD are being explored in clinical trials. Biomedical biomarkers are also being increasingly used in these trials to assess effectiveness.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)

Article Cell Biology

APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer's mice via cyclophilin A independently of amyloid-β

Axel Montagne et al.

Summary: This study demonstrates that APOE4 accelerates advanced-stage vascular dysfunction and neurodegeneration in old mice independently of amyloid-beta by activating the cyclophilin A pathway in pericytes. This has implications for the pathogenesis and treatment of vascular and neurodegenerative disorders in Alzheimer's disease.

NATURE AGING (2021)

Article Clinical Neurology

2021 Alzheimer's disease facts and figures

[Anonymous]

Summary: Alzheimer's disease has a significant impact on individuals and society as a whole, with a large number of patients in the United States and a potential for continued growth in the future. The value of unpaid caregivers has increased despite a decline in their numbers, and healthcare costs are on the rise. Racial and ethnic disparities in healthcare persist, highlighting the need for greater diversity in dementia care workforce and clinical trials.

ALZHEIMERS & DEMENTIA (2021)

Article Clinical Neurology

Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

David S. Knopman et al.

Summary: Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor due to divergent outcomes. One trial showed potential benefits from high doses of Aducanumab, while the other did not show any benefits. Further analysis is needed to determine the true efficacy as a treatment for Alzheimer's disease.

ALZHEIMERS & DEMENTIA (2021)

Article Multidisciplinary Sciences

Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease

Shun-Fat Lau et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2020

Jeffrey Cummings et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)

Article Multidisciplinary Sciences

CD22 blockade restores homeostatic microglial phagocytosis in ageing brains

John V. Pluvinage et al.

NATURE (2019)

Review Biochemistry & Molecular Biology

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Justin M. Long et al.

Review Clinical Neurology

A critical appraisal of amyloid-βtargeting therapies for Alzheimer disease

Francesco Panza et al.

NATURE REVIEWS NEUROLOGY (2019)

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2019

Jeffrey Cummings et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)

Article Biochemistry & Molecular Biology

TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease

Tyler K. Ulland et al.

Review Medicine, General & Internal

Alzheimer's disease

Philip Scheltens et al.

LANCET (2016)

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)